September 16, 2020 by Chain Drug Review
B. Douglas Hoey, COVID-19 vaccines, The National Community Pharmacists Association, Trump administration
Leading Headlines, Pharmacy

ALEXANDRIA, Va. — The National Community Pharmacists Association issued the following statement from CEO B. Douglas Hoey in reaction to the interim coronavirus vaccine immunization plan announced today by the Trump administration: “We’re pleased that this plan acknowledges and looks to utilize the essential nature of community pharmacies when rolling out coronavirus vaccine administration plans. Millions
July 22, 2020 by Chain Drug Review
B. Douglas Hoey, DIR fees, Trump administration
Leading Headlines, Pharmacy

ALEXANDRIA, Va. — In a letter to President Trump, National Community Pharmacists Association CEO B. Douglas Hoey says that as part of any efforts on drug pricing, the administration must eliminate back-door fees that insurance companies use to increase drug costs for seniors and gouge local pharmacies. “Insurance companies are using their prescription drug management divisions
September 12, 2019 by Chain Drug Review
e-cigarettes, FDA, Trump administration
Leading Headlines

WASHINGTON — The Trump administration on Wednesday announced plans to remove all flavored e-cigarettes from store shelves in an ever widening crackdown on vaping, as officials warned that sweet flavors had drawn millions of children into nicotine addiction. President Trump and top U.S. officials expressed major concerns about surging teenage use of e-cigarettes, and the
February 12, 2018 by Mark Baumgartner and Chain Drug Review
Centers for Medicare & Medicaid Services, Medicaid, Medicaid work requirements, Trump administration
2018, Issue 02-12-2018, Issues, News
WASHINGTON — The Trump administration has issued guidance that opens the door to work requirements for Medicaid recipients, a major change in the 50-year-old program offering a safety net for Americans living in or near poverty. The White House touted the move for Medicaid work requirements as “making a positive and lasting difference” in the
February 27, 2017 by Greg Jacobson and Chain Drug Review
ACA, ACA exchanges, Aetna, Affordable Care Act, Health and Human Services, health insurance exchanges, Humana, Mark Bertolini, Obamacare, Tom Price, Trump administration
2017, Issue 02-27-2017, Issues, News

WASHINGTON — Humana Inc.’s decision to pull out of the health insurance exchanges created by the Affordable Care Act threatens to cripple Obamacare before Republican lawmakers bent on its repeal can cobble together a replacement. The Humana decision came one day before the Trump administration issued a proposed rule that attempts to offer insurers more
February 6, 2017 by Scot Meyer and Chain Drug Review
Affordable Care Act, Department of Health and Human Services, HHS secretary, Orrin Hatch, Tom Price, Trump administration
2017, Issue 02-06-2017, Issues, News
WASHINGTON — Tom Price, an orthopedic surgeon, a six-term Republican congressman from Georgia and a fierce critic of the Affordable Care Act, faced tough questions from Democrats about ethical issues and policy priorities during his confirmation hearing. But at presstime it appeared that he would be approved as Secretary of the Department of Health and
January 16, 2017 by Brian Bossetta
Affordable Care Act, NACDS, National Association of Chain Drug Stores, National Governors Association, Pharmacy and Medically Underserved Areas Enhancement Act, pharmacy patient care, Trump administration
2017, Issue 01-16-2017, Issues, News
ARLINGTON, Va. — The National Association of Chain Drug Stores has sent a letter to the governors of all 50 states urging pharmacy patient care as a top priority in any changes to health care policy in 2017 and beyond. The most recent letter continues NACDS’ pro-patient, pro-pharmacy drumbeat to federal and state government decision
January 10, 2017 by Chain Drug Review
Affordable Care Act, Alex Gourlay, Alpesh Patel, Bob Narveson, Brian Nightengale, Brian Unmacht, Carmen Churcott, chain drug industry, Clint Mahlman, Donald Trump, Helena Foulkes, John Fiacco, John Figueroa, Lynne Fruth, Martin Otto, Mike Eby, Mike Wysong, National Association of Chain Drug Stores, Richard Brennan, Richard Willis, Robert Mauch, Steve Lawrence, Trump administration
Business, Featured Articles, Leading Headlines, Retail News

“The times they are a changin’,” Nobel laureate Bob Dylan sang in 1964. It’s as true now as it was 53 years ago, especially for the chain drug industry. With the incoming administration of Donald Trump, all bets are off with health care. The Affordable Care Act appears set for demise, but no one in
January 3, 2017 by David Farber and Chain Drug Review
Affordable Care Act, David Farber, Donald Trump, drug pricing, King & Spalding, Medicaid, Medicare, Obamacare, Trump administration
2017, Issue 01-02-2017, Issues, Leading Headlines, Opinion

The January 20, 2017, inauguration of President Trump as the nation’s 45th president is certain to bring with it changes in the health care environment, which may impact pharmacy in a variety of ways. As important as the new administration, however, is the fact that a “unified” government will take over in Washington, with Republicans
December 19, 2016 by Chain Drug Review
Affordable Care Act, American Pharmacists Association, Donald Trump, National Alliance of State Pharmacy Associations, National Association of Chain Drug Stores, National Community Pharmacists Association, Trump administration
Leading Headlines, Pharmacy, Retail News

WASHINGTON, D.C. — Sensing change in the air, a group of pharmacy associations have called on the incoming Trump administration and congressional leaders to recognize the role that pharmacies play in the nation’s health care system. In a letter to the new federal power structure, the National Association of Chain Drug Stores (NACDS), National Community